Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
|ClinicalTrials.gov Identifier: NCT00026468|
Recruitment Status : Withdrawn (Principle Investigator has left the University.)
First Posted : January 27, 2003
Last Update Posted : July 24, 2013
RATIONALE: Exisulind may be effective in preventing the development and growth of polyps in patients who have familial adenomatous polyposis.
PURPOSE: Randomized phase II/III trial to determine the effectiveness of exisulind in preventing the development and growth of polyps in patients who have familial adenomatous polyposis.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Small Intestine Cancer||Drug: exisulind||Phase 2 Phase 3|
- Determine the ability of exisulind to inhibit growth and development of duodenal adenomas in patients with familial adenomatous polyposis.
- Determine the effect on apoptosis in polyp vs mucosal tissue in these patients when treated with this drug.
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive oral exisulind 4 times daily.
- Arm II: Patients receive oral placebo 4 times daily. Treatment continues for 1 year.
PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis|
|Study Start Date :||July 1999|
|Actual Primary Completion Date :||July 1999|
|Actual Study Completion Date :||July 1999|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00026468
|Study Chair:||James A. DiSario, MD||University of Utah|